Tubulis Gmbh
Clinical trials sponsored by Tubulis Gmbh, explained in plain language.
-
New drug TUB-030 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…
Phase: PHASE1, PHASE2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New smart drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called TUB-040 for people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is an antibody-drug conjugate, meaning it delivers a powerful chemotherapy directly to cancer cell…
Phase: PHASE1, PHASE2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC